key: cord-0022028-8cxpv906
authors: Oh, Ki-Kwang; Adnan, Md.; Cho, Dong-Ha
title: Network Pharmacology-Based Study to Uncover Potential Pharmacological Mechanisms of Korean Thistle (Cirsium japonicum var. maackii (Maxim.) Matsum.) Flower against Cancer
date: 2021-09-29
journal: Molecules
DOI: 10.3390/molecules26195904
sha: ac53ff283352d905ce2134e771401c6bf8b79aca
doc_id: 22028
cord_uid: 8cxpv906

Cirsium japonicum var. maackii (Maxim.) Matsum. or Korean thistle flower is a herbal plant used to treat tumors in Korean folk remedies, but its essential bioactives and pharmacological mechanisms against cancer have remained unexplored. This study identified the main compounds(s) and mechanism(s) of the C. maackii flower against cancer via network pharmacology. The bioactives from the C. maackii flower were revealed by gas chromatography-mass spectrum (GC-MS), and SwissADME evaluated their physicochemical properties. Next, target(s) associated with the obtained bioactives or cancer-related targets were retrieved by public databases, and the Venn diagram selected the overlapping targets. The networks between overlapping targets and bioactives were visualized, constructed, and analyzed by RPackage. Finally, we implemented a molecular docking test (MDT) to explore key target(s) and compound(s) on AutoDockVina and LigPlot+. GC-MS detected a total of 34 bioactives and all were accepted by Lipinski’s rules and therefore classified as drug-like compounds (DLCs). A total of 597 bioactive-related targets and 4245 cancer-related targets were identified from public databases. The final 51 overlapping targets were selected between the bioactive targets network and cancer-related targets. With Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, a total of 20 signaling pathways were manifested, and a hub signaling pathway (PI3K-Akt signaling pathway), a key target (Akt1), and a key compound (Urs-12-en-24-oic acid, 3-oxo, methyl ester) were selected among the 20 signaling pathways via MDT. Overall, Urs-12-en-24-oic acid, 3-oxo, methyl ester from the C. maackii flower has potent anti-cancer efficacy by inactivating Akt1 on the PI3K-Akt signaling pathway.

The definition of cancer is that normal cells are damaged via an aberrant endogenous process such as an abnormality during DNA replication or instability of the DNA sequence, which transforms into malignancy [1] . The DNA damage responses represent chronic inflammation via the immune signaling pathway, which results in accelerating tumorigenesis [2] . The damaged normal cells undergo cellular senescence, triggering secretion in the inflammatory cytokines leading to cellular mechanical disruption [3, 4] . Because inflammation is a leading factor in causing pathological symptoms such as unknown severe pain, fatigue, and comorbidity in cancer patients, anti-inflammation strategies are thus key therapeutics [5, 6] . Current anti-inflammatory agents for cancer treatment NSAIDs, including Cox-2, due to fewer adverse effects and a lower mortality rate [7] . Most commonly, anti-cancer agents aim to inhibit DNA replication and induce cancer cell death; however, cancer chemotherapeutics also attack healthy cells resulting in serious side effects such as nausea, vomiting, hair loss, and fatigue [8] [9] [10] . On the other hand, traditional herbal plants with innovative bioactives and secondary metabolites play an essential role as effective anti-inflammatory, anti-oxidant, or anti-cancer agents [11] . For instance, plant extracts (Urtica membranaceae, Artemesia monosperma, and Origanum dayi Post) in combination with anti-cancer drugs showed enhanced potency against specific cancer cell lines (lung, breast, colon, and prostate cancer) without exposing normal lymphocytes and fibroblasts to cytotoxicity [12] . Herbal-derived bioactives possess fewer unwanted side effects than chemotherapy, and have led to new clinical drugs such as taxol from Taxus brevifolia L., vincristine from Catharanthus roseus G. Don, and Epipodophyllotoxin from Podophyllum peltatum L. [12, 13] .

C. maackii is a perennial herbal plant, belonging to the family of Compositae, and is widely distributed in the mountainous areas of Korea, Japan, and China [14] . Furthermore, Cirsium species have been reported to have diverse pharmacological activities such as antioxidant, anti-inflammation, anti-cancer, and hepatoprotection effects [15] [16] [17] [18] . Specifically, a C. maackii extract at a concentration of 200 µg/mL showed 36.89% inhibition against a breast cancer cell line (MDA-MB-231) [19] . Another study demonstrated that HepG2 cells treated with a MeOH extract of C. maackii have potent antioxidant efficacy against severe oxidant conditions [20] . Anti-inflammatory agents assist in protection against cancer development, thereby preventing cytokine storms [21] . It implies that anti-inflammatory compounds are important agonists to protect normal cells adjacent to tumor cells because they can block the overflow of cytokines. Until now, C. maackii flower compounds were identified by HPLC and had only been reported for anti-Alzheimer efficacy by inhibiting BACE1 [22] . Generally, the identification of polar and mid-polar compounds from extracts is based on HPLC due to its good separation capability [23, 24] . From a different perspective, we utilized GC-MS analysis to discover lipophilic bioactives, which mainly act as drug-like compounds and uptake efficiently into the cells. Lipophilicity is a significant physicochemical parameter that influences membrane permeability and affinity [25] . More importantly, GC-MS, along with the molecular docking test (MDT) and ADME (Absorption, Distribution, Metabolism, and Excretion) study, is an optimal analytical method to determine drug-like compounds [26] . At present, the bioactives and mechanisms of the C. maackii flower against cancer remain unknown. Hence, we aimed to uncover its potential bioactives with their fundamental mechanisms through network pharmacology.

Network pharmacology (NP) as a systemic method can analyze holistic bioactivetarget-disease relationships [27] . It can decipher the unknown mechanism(s) with "multiple targets", "multiple bioactives", instead of "one target", "one bioactive" [28] . This approach is a very effective method to recognize the mechanism of action for lead compounds discovered from herbal plants [29] . An existing drug may be re-modelled to bind on multiple targets with the concept of NP, thus it can be a guide for drug repurposing [30] . The NP application is a powerful tool to elucidate novel targets and bioactives from natural products, and is especially effective for anti-cancer research to investigate multi-target activity in biological pathways and interaction networks [31] . Here, we implemented NP to provide key bioactive(s), uppermost target(s), and potential mechanism(s) of the C. maackii flower against cancer. Mainly, the flower part of herbal plants are the most underexplored part compared to other parts such as leaves, roots, and stems. During the growing season of the C. maackii plant, the flowering part might be utilized as a source of essential bioactives or be taken as a functional food. In this study, we suggest that C. maackii flowers are valuable parts with potential anti-cancer compounds.

To prove their therapeutic value, we performed a GC-MS analysis, protein network investigation, and a molecular docking test (MDT). Its brief processes are discussed below.

Firstly, bioactives from the C. maackii flower were identified by GC-MS analysis and screened to find drug-likeness compounds via an in silico tool. Then, targets associated with bioactives or cancer were identified through public databases, and final overlapping targets were utilized to analyze protein-protein interaction (PPI) and the highest degree of a target. Thirdly, a signaling pathway-target protein-bioactive (S-T-B) relationship against cancer was identified by networking analysis. Lastly, we found the most potent bioactive and a hub target to alleviate cancer severity by exploring the molecular mechanism of the C. maackii flower based on MDT. The workflow diagram is displayed in Figure 1 . 

A total of 34 bioactives in the C. maackii flower were identified by GC-MS analysis (Figure 2 ), and the name of compounds, PubChem ID, retention time (mins), and peak area (%) are listed in Table 1 . All 34 compounds were accepted by Lipinski's rules (Molecular Weight ≤ 500 g/mol; Moriguchi octanol-water partition coefficient ≤ 4.15; Number of Nitrogen or Oxygen ≤ 10; Number of NH or OH ≤ 5), and all bioactives corresponded with the standard of "Abbott Bioavailability Score (>0.1)" through SwissADME. The TPSA (Topological Polar Surface Area) value of all bioactives was also accepted ( Table 2 ). Protective cell against pathogens [44] PCIDB: PhytoChemical Interactions DB. 

A total of 309 targets from SEA and 396 targets from STP connected to 34 bioactives were identified (Supplementary Table S1 ). The Venn diagram showed that 108 targets overlapped between the two public databases (Supplementary Table S1) ( Figure 3A ). 

A total of 4245 targets related to cancer were selected via retrieval from TTD and OMIM databases (Supplementary Table S2 ). The Venn diagram results revealed 51 overlapping targets that were selected between 4245 targets associated with cancer and 108 overlapping targets ( Figure 3B ) (Supplementary Table S3 ).

From STRING analysis, 46 out of 51 overlapping targets were directly related to cancer occurrence and development, indicating 46 nodes and 145 edges ( Figure 4 ). The five targets removed (PAM, EPHX1, PPARD, KDM5C, and BCHE) had no connectivity to the overlapping 51 targets. In PPI networks, the Akt1 target was the highest degree (29) and was considered a hub target (Table 3 ). 

The output of KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis revealed that 20 signaling pathways were associated with 24 targets (False Discovery Rate < 0.05). The 20 signaling pathways were directly connected to cancer, suggesting that these 20 signaling pathways might be the noteworthy pathways of the C. maackii flower against cancer. The descriptions of 20 signaling pathways are displayed in Table 4 . Additionally, a bubble chart suggested that the PI3K-Akt signaling pathway might be a hub signaling pathway of the C. maackii flower against cancer ( Figure 5 ). Among the 20 signaling pathways, the Akt1 target was associated with 18 signaling pathways, representing the highest degree of value. Most importantly, Akt1 is directly related to the PI3K-Akt signaling pathway whereas both the PPAR signaling pathway and the Calcium signaling pathway are not correlated with Akt1. 

The S-T-B network of the C. maackii flower is exhibited in Figure 6 . There were 20 pathways, 24 targets, and 19 bioactives (63 nodes and 204 edges). The nodes represented a total of three elements: Signaling pathways-Target protein-Bioactive (S-T-B). The edges represented relationships of a total number of three elements. The S-T-B relationship suggested that the network might interact with therapeutic efficacy against cancer. Regarding the 20 signaling pathways, the highest degree among targets was "Akt1" with 18 degrees, and the highest degree among bioactives was "Urs-12-en-24-oic acid, 3-oxo-, methyl ester" with 36 degrees (Table 5 ). The Akt1 protein was related to two bioactives (Urs-12-en-24-oic acid, 3-oxo-, methyl ester and α-Tocopherol), the VEGFA target to three bioactives (Allyl stearate, Isopropyl palmitate, and Methyl 3,6-anhydro hexopyranoside #), and the PRKCA target with seven bioactives (Allyl stearate, Isopropyl palmitate, Pentyl isobutyrate, 9-Heptadecanone, Palmitic acid, Stearic acid, and d-Lyxo-d-manno-nononic-1,4-lactone). MDT was performed to verify the affinity of target protein(s) and biactive(s), which displayed the docking figure of a hub target-the uppermost bioactive (Figure 7) . The Akt1 protein (PDB ID: 5KCV) connected to two compounds on the PI3K-Akt signaling pathway was subjected to MDT. It was observed that Urs-12-en-24-oic acid, 3-oxo-, methyl ester (−12.8 kcal/mol) docked on the Akt1 protein (PDB ID: 5KCV) manifested the highest binding energy, followed by α-Tocopherol (−5.8 kcal/mol). The docking detail results of two bioactives are shown in Table 6 . The MDT score of three bioactives on the VEGFA protein (PDB ID: 3V2A) was analyzed in the "Homo Sapiens" mode. It was revealed that Methyl 3,6-anhydro hexopyranoside # (−5.2 kcal/mol) docked on the VEGFA protein (PDB ID: 3V2A) exhibited the highest binding energy followed by Allyl stearate (−5.1 kcal/mol) and Isopropyl palmitate (−5.1 kcal/mol). The docking detail results of three bioactives are shown in Table 7 . The MDT score of seven bioactives on the PRKCA protein (PDB ID: 3IW4) was analyzed in the "Homo Sapiens" mode. It was exposed that d-Lyxo-d-manno-nononic-1,4-lactone (−6.9 kcal/mol) docked on the PRKCA protein (PDB ID: 3IW4) demonstrated the highest binding energy, followed by Isopropyl palmitate (−6.3 kcal/mol), Stearic acid (−6.2 kcal/mol), Allyl stearate (−6.2 kcal/mol), 9-Heptadecanone (−5.4 kcal/mol), Pentyl isobutyrate (−5.0 kcal/mol), and Palmitic acid (−4.8 kcal/mol). The docking detail results of seven bioactives are shown in Table 8 . Collectively, both VEGFA (PDB ID: 3V2A) and PRKCA proteins (PDB ID: 3IW4) showed that the affinity of each bioactive did not give a valid binding score (>−7.0 kcal/mol) [45] . Asp257, Gly255, Ile256 Glu44 

A key bioactive (Urs-12-en-24-oic acid, 3-oxo-, methyl ester) associated with the PI3K-Akt signaling pathway revealed the greatest binding score (−12.8 kcal/mol) on Akt1 (PDB ID: 5KCV). The 13 positive controls on Akt1 (PDB ID: 5KCV) are as follows. The MDT score of BAY1125976 (PubChem ID: 70817911) was the highest score with −9.1 kcal/mol, followed by Miransertib (PubChem ID: 53262401; −9.0 kcal/mol)), Akti-1/2 (PubChem ID: 135398501; −8. Table 9 . 

Additionally, the toxicological properties of Urs-12-en-24-oic acid, 3-oxo-, methyl ester were predicted by the admetSAR online tool. Our result suggested that the bioactive did not disclose Ames toxicity, carcinogenic properties, acute oral toxicity, or rat acute toxicity properties (Table 10) . Table 10 . Toxicological properties of the uppermost bioactive on AKT1 (PDB ID: 5KCV) in MDT.

Compound Name Urs-12-en-24-oic acid, 3- 

The S-T-B network suggested that the therapeutic efficacy of the C. maackii flower against cancer was directly associated with 20 signaling pathways, 24 targets, and 19 bioactives. Through the network, we identified the most significant protein (Akt1) associated with the occurrence and development of cancer and a bioactive (Urs-12-en-24-oic acid, 3-oxo-, methyl ester) from the C. maackii flower. From a bubble chart, we identified a hub signaling pathway (PI3K-Akt signaling pathway) connected to the Akt1 target, indicating the lowest rich factor among 20 signaling pathways. A report demonstrated that the activated PI3K-Akt signaling pathway accelerates tumor cell proliferation, invasion, and metastasis, inhibiting apoptosis [46] . Furthermore, it was found that the Akt1 target was overexpressed in 15 out of 24 human hepatocellular carcinomas (63.3%) confirmed using PCR analysis through Northern blot [47] . Another research study suggested that the PI3K-Akt signaling pathway's antagonists are potential anti-cancer candidates to regulate acute and chronic inflammatory responses [48] .

In the S-T-B network, Urs-12-en-24-oic acid, 3-oxo-, methyl ester had the highest degree of value and was considered the uppermost bioactive of the C. maackii flower against cancer. Urs-12-en-24-oic acid, 3-oxo-, methyl ester is categorized into boswellic acids used widely as anti-inflammatory agents, including as an anti-cancer treatment. Additionally, the boswellic acids have potent anti-cancer efficacy against diverse malignant cancers [49, 50] . The KEGG pathway enrichment analysis of 24 targets suggested that a total of 20 signaling pathways were involved in cancer occurrence and development. The relationships of the 20 signaling pathways with cancer are concisely discussed as follows. In the Peroxisome Proliferator-Activated Receptor (PPAR) signaling pathway, the activation of the PPAR signaling pathway functions as an anti-inflammatory agent, which can overwhelm the metabolic energy balance of cancer cells by inhibiting the fatty acid synthesis and accelerating fatty acid oxidation [51, 52] . In the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, MAPK inhibitors are efficient blockers to reduce pro-inflammatory cytokines and enhance the anti-cancer effect, particularly on human pancreatic cancer cells [53, 54] . In the Rap1 (Ras-associated protein-1) signaling pathway, Rap1 promotes cytokine production during the inflammatory condition, which leads to tumor progression in human colorectal cancer [55, 56] . Regarding the alcium signaling pathway, calcium is a significant second messenger to regulate inflammation; hence, blockers of the calcium channel can induce cancer cell death [57, 58] . In the Cyclic AMP (cAMP) signaling pathway, an increased cAMP level has an anti-inflammatory effect, where the increased level can regulate DNA damage, DNA repair, and apoptosis of cancer cells [59, 60] . Concerning the Hypoxia-Inducible Factor-1 (HIF-1) signaling pathway, HIF-1 is a central regulator to stimulate the production of inflammation. HIF-1 overexpression is related to increased tumor growth [61, 62] . In the sphingolipid signaling pathway, sphingolipid is implicated in the inflammatory response, which has been involved in cancer cell proliferation [63, 64] . In the Phospholipase D (PLD) signaling pathway, PLD inhibition can induce two functions, namely anti-inflammation and anti-cancer. Mainly, the blocking of PLD during chemotherapy can sensitize one to chemotherapeutics [65, 66] . Regarding the Phosphoinositide 3-kinase-Akt (PI3K-Akt) signaling pathway, inhibition of the PI3K-Akt signaling pathway reduces the severity of inflammation in mice. This strategy is a promising mechanism for the treatment of cancers such as lung cancer, colorectal cancer, renal cancer, prostate cancer, triple-negative breast cancer, mucinous adenocarcinoma of the ovary, and skin cancer [67, 68] . In the AMP-activated protein kinase (AMPK) signaling pathway, AMPK activation suppresses inflammatory responses and dampens cancer growth with cell metabolism and the cell cycle [69, 70] . Regarding the Vascular Endothelial Growth Factor (VEGF) signaling pathway, VEGF is a core mediator in the formation of new blood vessels for cancer cells; thereby, cancer cells can survive, grow, and metastasize [71] . In the B cell receptor (BCR) signaling pathway, B cells are involved in the inflammatory T cell receptor, which is implicated in antibody production [72] . B cells or BCR-associated kinases may function with anti-cancer activity via B cells activation [73] . In the Fc epsilon RI signaling pathway, the expression of Fc epsilon on mast cells stimulates immunoglobulin E, leading to type 1 hypersensitivity-induced local inflammatory responses at the tumor sites [74] . In the insulin signaling pathway, insulin-resistant patients undergo excessive production of reactive oxygen species (ROS) that can harm DNA attributed to carcinogenesis [75] . In the estrogen signaling pathway, estrogen exposure to chronic inflammatory disease activity is a key risk in breast cancer progression [76] . With regards to the prolactin signaling pathway, prolactin functions as a cytokine immune system, especially in breast cancer, which has the strongest correlation with an increased expression level of prolactin and prolactin receptors [77, 78] . In the thyroid signaling pathway, the optimal regulation of the cellular thyroid hormone is essential for an adequate role of immune cells during inflammation [79] . In terms of the adipocytokine signaling pathway, adipocytokine is an inflammatory mediator during immune-associated diseases, which accelerates cancer progression and metastasizes from organ to organ [80] . In the Relaxin signaling pathway, Relaxin alleviates the inflammatory severity and diminishes the amount of leucocytes and the expression level of cytokines [81] . In terms of the Advanced Glycation End-product (AGE)-Advanced Glycation End-product Receptor (RAGE) signaling pathway in diabetic complications, RAGE can stimulate inflammatory responses by binding with AGEs [82] . The inhibitor (papaverine) of RAGE is a promising target for anti-cancer activity, which blocks nuclear factor kappa B (NF-κB) [83] .

The C. maackii flowers were collected from Mihogil of Bomunmyeon (Latitude: 36 

The C. maackii flower was dried in a shady area at room temperature (20-22 • C) for 7 days, and dried leaves were powdered using an electric blender (Shinil, Cheonan, Korea). Approximately 50 g of C. maackii flower powder was soaked in 800 mL of 100% methanol (Daejung, Seohaean, Korea) for 5 days and repeated 3 times to collect extraction. The solvent extract was collected, filtered, and evaporated using a vacuum evaporator (RV8, IKA, Staufen, German). The evaporated sample was dried under a boiling water bath (HB10, IKA, Staufen, German) at 40 • C to obtain the extract.

Agilent 7890A (Agilent, Santa Clara, CA, USA) was used to carry out the GC-MS analysis. GC was equipped with a DB-5 (30 m × 0.25 mm × 0.25 µm) capillary column (Agilent, Santa Clara, CA, USA). Initially, the instrument was maintained at a temperature of 100 • C for 2.1 min. The temperature rose to 300 • C at a rate of 25 • C/min and was maintained for 20 min. The injection port temperature and helium flow rate were sustained at 250 • C and 1.5 mL/min, respectively. The ionization voltage was 70 eV. The samples were injected in the split mode at 10:1. The MS scan range was set at 35-900 (m/z). The fragmentation patterns of mass spectra were compared with those stored in the W8N05ST Library MS database. The percentage of each compound was calculated from the relative peak area of each compound in the chromatogram. The concept of integration was used with the ChemStation integrator (Agilent, Santa Clara, CA, USA) algorithms (analyzed 19 May 2021) [84] .

The bioactives from the C. maackii flower were identified by utilizing GC-MS analysis. Then, the GC-MS-detected bioactives were filtered in accordance with Lipinski's rules through SwissADME (http://www.swissadme.ch/) (accessed on 3 June 2021) to confirm the "Drug-likeness" physicochemical properties. PubChem (https://pubchem.ncbi.nlm. nih.gov/) (accessed on 3 June 2021) was utilized to select the SMILES (Simplified Molecular Input Line Entry System) bioactives.

Targets connected to the bioactives were selected through both the Similarity Ensemble Approach (SEA) (http://sea.bkslab.org/) (accessed on 7 June 2021) [85] and Swiss Target Prediction (STP) (http://www.swisstargetprediction.ch/) (accessed on 9 June 2021) [86] with the "Homo Sapiens" setting, both of which are based on SMILES. The cancer-related targets in humans were obtained with keywords (cancer/tumor/neoplasia/carcinoma) from TTD (http://db.idrblab.net/ttd/) (accessed on 12 June 2021) and OMIM (https: //www.omim.org/) (accessed on 13 June 2021). The overlapping targets between compounds of the C. maackii flower and cancer targets were illustrated by VENNY 2.1 ( https://bioinfogp.cnb.csic.es/tools/venny/) (accessed on 14 June 2021).

For the final overlapping targets, STRING (https://string-db.org/) (accessed on 16 June 2021) [87] was utilized to analyze the PPI network. Thereby, RPackage was used to identify the degree of value. Then, signaling pathways on STRING were visualized by RPackage, a hub signaling pathway (lowest rich factor) related to a hub target (highest degree of value from PPI).

Both the hub target (the highest degree of value among 20 signaling pathways) and the uppermost bioactive were identified via the S-T-B network. The S-T-B networks were utilized to construct a size map, based on the degree of values. In this size map, green rectangles (nodes) represented signaling pathways, pink triangles (nodes) represented targets, and orange circles (nodes) represented bioactives. The circle size represented the degree value, the size of pink triangles represented the number of connectivity with signaling pathways, and the size of orange circles represented the number of connections with targets. The merged networks were constructed using RPackage.

Four targets of a hub signaling pathway, i.e., Akt1 (PDB ID: 5KCV), VEGFA (PDB ID: 3V2A), PRKCA (PDB ID: 3IW4), and PHLPP1 (PDB ID: N/A), were selected on STRING via RCSB PDB (https://www.rcsb.org/) (accessed on 19 June 2021). Specifically, the PHLPP1 protein structure was not determined; thereby, the PDB ID was not uploaded in the .pdb format. Thus, the final three proteins selected in the .pdb format were converted into the .pdbqt format via Autodock (http://autodock.scripps.edu/) (accessed on 22 June 2021) [88] . 

The ligand molecules were converted from sdf in PubChem into the .pdb format using Pymol, and the ligand molecules were converted into the .pdbqt format through Autodock.

The ligand molecules were docked with targets utilizing autodock4 by setting up an energy range of 4 and exhaustiveness at 8 as the default to obtain 10 different positions of ligand molecules [89] . The center (the position of the middle coordinate point) in the target was X: −12.677, Y: 2.931, Z: −13.145 on AKT1 (PDB ID: 5KCV). The grid box size was set to 40 Å × 40 Å × 40 Å. The 2D binding interactions were used with LigPlot+ v.2.2 (https://www.ebi.ac.uk/thornton-srv/software/LigPlus/) (accessed on 23 June 2021) [90] . After docking, ligands of the lowest binding energy (highest affinity) were selected to visualize the ligand-protein interaction in Pymol.

Toxicological properties of the key bioactive were established using the admetSAR web-service tool (http://lmmd.ecust.edu.cn/admetsar1/predict/) (accessed on 24 June 2021) [91] because toxicity is an essential factor in developing new drugs. Hence, Ames toxicity, carcinogenic properties, acute oral toxicity, and rat acute toxicity were predicted by admetSAR.

The bioactives and mechanisms of C. maackii flowers against cancer were firstly uncovered through network pharmacology. The findings suggested that 20 signaling pathways, 24 targets, and 19 bioactives are connected to cancer. Of these, the PI3K-Akt signaling pathway, Akt1, and Urs-12-en-24-oic acid, 3-oxo-, methyl ester were the hub signaling pathway, hub target, and key bioactive of C. maackii flowers against cancer, respectively. Furthermore, Urs-12-en-24-oic acid, 3-oxo-, methyl ester has the most potent efficacy on the Akt1 target protein than 13 other standard ligands. This study suggests that the mechanism of the C. maackii flower against cancer might strengthen anti-inflammatory responses by inactivating the PI3K-Akt signaling pathway, bound to Urs-12-en-24-oic acid, 3-oxo-, methyl ester on Akt1. From this viewpoint, we propose that C. maackii flowers can be utilized as functional or medicinal resources against cancer.

Supplementary Materials: The following are available online, Table S1: The 309, 396, and 108 targets from SEA, STP, and overlapping targets between SEA and STP, respectively. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: All data generated or analyzed during this study are included in this published article (and its Supplementary Information Files) .

Acknowledgments: This research was acknowledged by the Department of Bio-Health Convergence, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Korea.

There is no conflict of interest.

Sample Availability: Samples of described compounds are available from the authors. 

The molecular biology of cancer

DNA Damage Response and Immune Defense: Links and Mechanisms

Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines

The high costs of low-grade inflammation: Persistent fatigue as a consequence of reduced cellular-energy availability and non-adaptive energy expenditure

Inflammation and cancer

Anti-inflammatory agents for cancer therapy

Inactivation of nuclear factor κB by MIP-based drug combinations augments cell death of breast cancer cells

Introduction to Cancer Chemotherapeutics

Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients

Anti-Inflammatory Plant Natural Products for Cancer Therapy

Medicinal Plants: Their Use in Anticancer Treatment

Medicinal Plants and Cancer Chemoprevention

Korean Thistle (Cirsium japonicum var. maackii (Maxim.) Matsum.): A Potential Dietary Supplement against Diabetes and Alzheimer's Disease

Components and antioxidant activity of fruits of Cirsium palustre and C. rivulare

Cirsium japonicum elicits endothelium-dependent relaxation via histamine H1-receptor in rat thoracic aorta

Anticancer activity and quantitative analysis of flavone of Cirsium japonicum DC

Hepatoprotective phenylethanoid glycosides from Cirsium setosum

Beneficial effects of a medicinal herb, Cirsium japonicum var. maackii, extract and its major component, cirsimaritin on breast cancer metastasis in MDA-MB-231 breast cancer cells

Protective effects of flavonoids isolated from Korean milk thistle Cirsium japonicum var. maackii (Maxim.) Matsum on tert-butyl hydroperoxide-induced hepatotoxicity in HepG2 cells

Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor

Isolation and Quantitative Analysis of BACE1 Inhibitory Compounds from Cirsium maackii Flower

HPLC Separation of Different Groups of Small Polar Compounds on a Novel Amide-Embedded Stationary Phase

Tentative identification of polar and mid-polar compounds in extracts from wine lees by liquid chromatography-tandem mass spectrometry in high-resolution mode

Lipophilicity as a Central Component of Drug-Like Properties of Chalchones and Flavonoid Derivatives

Estimation of drug-likeness properties of GC-MS separated bioactive compounds in rare medicinal Pleione maculata using molecular docking technique and SwissADME in silico tools

Network pharmacology of bioactives from Sorghum bicolor with targets related to diabetes mellitus

Network pharmacology: The next paradigm in drug discovery

Target recognition and network pharmacology for revealing anti-diabetes mechanisms of natural product

Drug Repositioning Through Network Pharmacology

Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products

Identification and Bioactivities of Two Endophytic Fungi Fusarium fujikuroi and Aspergillus tubingensis from Foliar Parts of Debregeasia salicifolia

Composition and antimicrobial activities of the leaf and flower essential oils of Lippia chevalieri and Ocimum canum from Burkina Faso

Palmitic acid inhibits inflammatory responses in lipopolysaccharide-stimulated mouse peritoneal macrophages

3-Hydroxypropionic Acid as an Antibacterial Agent from Endophytic Fungi Diaporthe phaseolorum

Investigation of fatty acid esters to replace isopropyl myristate in the sterility test for ophthalmic ointments

Bactericidal activity of self-assembled palmitic and stearic fatty acid crystals on highly ordered pyrolytic graphite

Analytical method development and validation of teneligliptin by rp-uflc. Res

Non-Antioxidant Properties of α-Tocopherol Reduce the Anticancer Activity of Several Protein Kinase Inhibitors In Vitro

A network pharmacology study on main chemical compounds from Hibiscus cannabinus L. leaves

Identification of anti-inflammatory constituents from Kalimeris indica with UHPLC

Rothmanniamide and other constituents from the leaves of Rothmannia hispida (K.Schum.) fagerl. (Rubiaceae) and their chemophenetic significance

Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus

Virtual Screening of Chemical Compounds for Discovery of Complement C3 Ligands

PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers

Overexpression of Akt-1 gene in human hepatocellular carcinoma

Akt1 is critical for acute inflammation and histamine-mediated vascular leakage

Evaluation of Antimicrobial Activity of Cissus quadrangularis L. stem extracts against Avian Pathogens and Determination of its Bioactive Constituents using GC-MS

Boswellic acids as natural anticancer medicine: Precious gift to humankind

Role of PPARs in inflammatory processes associated with metabolic syndrome (Review)

Anticancer Properties of PPARα-Effects on Cellular Metabolism and Inflammation

MAPK signalling pathways as molecular targets for anti-inflammatory therapy-From molecular mechanisms to therapeutic benefits

Mitogen-activated protein kinase inhibition enhances the antitumor effects of sporamin in human pancreatic cancer cells

Rap1 induces cytokine production in pro-inflammatory macrophages through NFκB signaling and is highly expressed in human atherosclerotic lesions

The downregulation of Rap1 GTPase-activating protein is associated with a poor prognosis in colorectal cancer and may impact on tumor progression

Endothelial Cell Calcium Signaling during Barrier Function and Inflammation

Calcium signaling and the therapeutic targeting of cancer cells

The effects of increased cAMP content on inflammation, oxidative stress and PDE4 transcripts during Brucella melitensis infection

A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer

Hypoxia inducible factor as a central regulator of metabolism-Implications for the development of obesity

Evaluation of HIF-1 inhibitors as anticancer agents

Sphingolipids in inflammation: Pathological implications and potential therapeutic targets

Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance

Functional Regulation of Phospholipase D Expression in Cancer and Inflammation

Phospholipase D and Its Essential Role in Cancer

PI3K signalling in inflammation

Targeting PI3K in cancer: Mechanisms and advances in clinical trials

Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway

AMPK as a Potential Anticancer Target-Friend or Foe?

VEGF as a Key Mediator of Angiogenesis in Cancer

Targeting B cell receptor signalling in cancer: Preclinical and clinical advances

Chimeric immunoglobulin E reactive with tumor-associated antigen activates human FcεRI bearing cells

Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms

Hyperprolactinemia and autoimmune diseases

Prolactin and cancer: Has the orphan finally found a home?

Thyroid hormone in inflammation

Bone Marrow Adipocytes, Adipocytokines, and Breast Cancer Cells: Novel Implications in Bone Metastasis of Breast Cancer

Emerging roles for the relaxin/RXFP1 system in cancer therapy

Pro-inflammatory AGE-RAGE signaling is activated during arousal from hibernation in ground squirrel adipose

In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system

Active ingredients and mechanisms of Phellinus linteus (grown on Rosa multiflora) for alleviation of Type 2 diabetes mellitus through network pharmacology

Relating protein pharmacology by ligand chemistry

SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules

STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19

Multiple ligand-protein interaction diagrams for drug discovery

0: Web-service for prediction and optimization of chemical ADMET properties